Certain Genomic Tests May Soon Be Reimbursable for Breast Cancer Patients in Germany

Certain Genomic Tests May Soon Be Reimbursable for Breast Cancer Patients in Germany
Techniker Krankenkasse, one of the largest healthcare insurers in Germany, will begin reimbursing their breast cancer patients for genomic tests, announced Agendia, a diagnostics company that offers a test called MammaPrint. The insurance company has joined the selective contract — a reimbursement instrument of Germany’s healthcare system — of the German Pathologists Organization for the reimbursement of genomic testing costs to breast cancer patients. This contract includes only diagnostic tests with CE marking, meaning that they comply with the European Union’s health, safety, and environmental protection requirements, MammaPrint being one of them. “This sends a good message; it helps our patients and supports our work,” Burkhard Otremba, MD, from Onkologische Praxis in Oldenburg, Germany, said in a press release. MammaPrint looks at the activity of the 70 most important genes associated with breast cancer recurrence to classify early-stage breast cancer patients according to their risk of having their cancer return or spread to other parts of the body (metastasis) within the first 10 years after diagnosis. The test was validated i
Subscribe or to access all post and page content.